CanAg Diagnostics Overview

  • Founded
  • 1992

Founded
  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

CanAg Diagnostics General Information

Description

Developer of immunological reagents. The company develops monoclonal antibodies for the treatment of cancer, brain damage and tumors.

Contact Information

Website
www.canag.se
Formerly Known As
Centocor Diagnostics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare
Acquirer
Fujirebio Diagnostics
Primary Office
  • Elof Lindälvs gata 13
  • 414 55 Gothenburg
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CanAg Diagnostics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 31-May-2006 Completed Generating Revenue
2. Angel (individual) 01-Jan-2001 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view CanAg Diagnostics’s complete valuation and funding history, request access »

CanAg Diagnostics Patents

CanAg Diagnostics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20040176577-A1 Monoclonal antibody for classifiying squamous cell carcinoma antigen (scca) species and diagnosis of cell proliferative disorders Abandoned 10-Sep-2002 000000000
US-20080057520-A1 Monoclonal antibody for detecting squamous cell carcinoma antigen (scca); diagnostic indicator for cancer screening; immunodiagnostics Abandoned 10-Sep-2002 000000000
US-20050089534-A1 Immunogenic rafts, lipid enriched membrane domains, and their use in cancer therapy;tumor protein(-s) and/or glycosphingolipid(-s); vaccine; immunotherapy Abandoned 14-Aug-2002 00000000000
US-6555327-B1 Immunoas say for specific determination of total calcium binding protein s100 or the different isoforms of s100 in serum, plasma, cerebrospinal or other body fluids Expired - Lifetime 28-Aug-1998 000000000
DE-69931054-T2 Monoclonal antibodies against s100 Expired - Lifetime 28-Aug-1998 C07K16/18
To view CanAg Diagnostics’s complete patent history, request access »

CanAg Diagnostics Executive Team (3)

Name Title Board Seat Contact Info
Börje Karlsson Co-Founder
Leif Lindholm Co-Founder
You’re viewing 2 of 3 executive team members. Get the full list »

CanAg Diagnostics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Industrifonden Venture Capital Minority 000 0000 000000 0
Líftæknisjóðurinn MP BIO hf Venture Capital Minority 000 0000 000000 0
To view CanAg Diagnostics’s complete investors history, request access »